As disclosed in the U.S. SEC, a form for the sale of 13,987 shares of Quest Diagnostics Inc by Michael Prevoznik was filled. Michael Prevoznik now serves as a SVP & General Counsel of the public firm. The public report was filled on 20-03-2017. The reported shares were sold at average $100.0 for share, and are with market value of $1,398,700 U.S Dollars. This is not his first insider trade, in the last month, he sold another 4,948 shares worth $486,095 USD. Currently, Mr. Michael, holds 45,130 shares, which accounts for 0.03% of the Company’s market capitalization.
Coca-Cola Bottling Co. Consolidated produces, markets and distributes nonalcoholic beverages, primarily products of The Coca-Cola Company, which include beverage brands. The company has market cap of $1.83 billion. The Firm is an independent Coca-Cola bottler in the United States. It has a 47.33 P/E ratio. The Company’s divisions are Nonalcoholic Beverages and All Other.
Cramer Rosenthal Mcglynn Llc holds 0.39% of its portfolio in Coca-Cola Bottling Co. Consolidated for 148,087 shares. Cim Investment Mangement Inc owns 1,415 shares or 0.09% of their US portfolio. Moreover, Carroll Financial Associates Inc. has 0.07% invested in the company for 2,827 shares. The Pennsylvania-based Tfs Capital Llc has invested 0.06% in the stock. Symphony Asset Management Llc, a California-based fund reported 2,638 shares.
Analysts await Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE) to report earnings on May, 9.
The stock increased 0.62% or $1.2 during the last trading session, reaching $195.23. About 44,927 shares traded. Coca-Cola Bottling Co. Consolidated (NASDAQ:COKE) has risen 27.44% since August 11, 2016 and is uptrending. It has outperformed by 18.64% the S&P500.
Quest Diagnostics Incorporated is a well-known provider of diagnostic information services. The company has market cap of $13.68 billion. The Firm operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. It has a 21.84 P/E ratio. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks , health plans, employers and accountable care organizations (ACOs).
Analysts await Quest Diagnostics Inc (NYSE:DGX) to report earnings on April, 20. They expect $1.18 earnings per share, up 5.36% or $0.06 from last year’s $1.12 per share. DGX’s profit will be $162.78 million for 21.01 P/E if the $1.18 EPS becomes a reality. After $1.31 actual earnings per share reported by Quest Diagnostics Inc for the previous quarter, Wall Street now forecasts -9.92% negative EPS growth.
Since November 15, 2016, it had 0 insider buys, and 9 insider sales for $16.68 million activity. Doherty Catherine T. had sold 1,615 shares worth $152,858. Another trade for 42,643 shares valued at $3.63 million was sold by PFEIFFER GARY M. On Wednesday, March 1 PREVOZNIK MICHAEL E sold $45,952 worth of Quest Diagnostics Inc (NYSE:DGX) or 470 shares. $191,016 worth of stock was sold by ZIEGLER JOHN B on Wednesday, February 22.
Among 11 analysts covering Quest Diagnostics (NYSE:DGX), 5 have Buy rating, 1 Sell and 5 Hold. Therefore 45% are positive. Quest Diagnostics has $108 highest and $68 lowest target. $83.89’s average target is -15.41% below currents $99.17 stock price. Quest Diagnostics had 20 analyst reports since August 4, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Sector Perform” rating and $70 target in Friday, January 29 report. The company was upgraded on Tuesday, January 3 by Mizuho. Goldman Sachs upgraded Quest Diagnostics Inc (NYSE:DGX) on Monday, December 12 to “Buy” rating. On Friday, September 9 the stock rating was initiated by Citigroup with “Neutral”. The stock of Quest Diagnostics Inc (NYSE:DGX) has “Hold” rating given on Tuesday, August 18 by Zacks. The rating was upgraded by Bank of America on Thursday, March 16 to “Neutral”. On Wednesday, August 31 the stock rating was downgraded by Mizuho to “Neutral”. Mizuho maintained Quest Diagnostics Inc (NYSE:DGX) on Friday, October 21 with “Neutral” rating. UBS upgraded the shares of DGX in report on Monday, November 14 to “Buy” rating. The stock has “Sector Perform” rating by RBC Capital Markets on Friday, October 23.
